Newsletter

Pol. Merkur. Lek (Pol. Med. J.), 2016, XL/237: 198-201 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2016, XL/237: 198-201

Title: The treatment of hypogonadism and maintenance of fertility in men 

Author: Rabijewski M.  

More details

12/237

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

The treatment of hypogonadism and maintenance of fertility in men


Rabijewski M.

Department of Internal Diseases, Diabetology and Endocrinology, Medical University of Warsaw, Poland

In past few years we observed the increasing of population of men, who are treated with testosterone due to hypogonadism associated with aging but the most of them have no indications to testosterone replacement therapy. The classical symptoms of hypogonadism including depression, loss of libido, erectile dysfunction, and fatigue may be related to any others diseases. The increase in prevalence of androgenic anabolic steroids specifically among younger athletes is also observed. Exogenous testosterone and anabolic androgenic steroids can inhibit the hypothalamic-pituitary-gonadal axis leading to decreasing of endogenous testosterone synthesis and impaired spermatogenesis. In hypogonadal men who are in reproduction age the goal of therapy should be not only replacement therapy but also achiving and/or maintaining of spermatogenesis. Human chorionic gonadotropin (hCG) and selective estrogens receptor modulators (SERM) are efficacy in treatment of clinical signs and symptoms of hypoigonadism, has been shown to reverse spermatogenesis disturbances and can to maintain elevated intratesticular testosterone levels necessary to optimal spermatogenesis.

Key words: hypogonadism, men, gertility, testosterone

Pol Med J, 2016; XL (237); 198–201